Abstract:8522 Background: Our previous study revealed that high diagnostic accuracy for early stage lung cancer could be obtained in plasma samples with ultrasensitive DNA hypermethylation detection methods called MOB-qMSP. In this study, we sought to validate and also improve the diagnostic accuracy of lung cancer screening with modified MOB-qMSP approach in Chinese patients. We also develop a lung cancer specific gene panel for Chinese patients. Methods: We included patients with small lung nodules (less than 3cm in diameter) on CT scan screening and conducted a case-control study. Cases (n=138) had pathological confirmation of Non-Small Cell Lung Cancer (NSCLC) lesions staged IA or IB. Controls (n=65) had pathological confirmation of non-cancerous lesions. Plasma samples were obtained pre-operatively. Promoter methylation of eight lung cancer-specific genes (CDO1, TAC1, SOX17, HOXA7, HOXA9, GATA4, GATA5 and PAX5B) was detected using nanoparticle-based DNA extraction (MOB) followed by qMSP. Results: DNA methylation was detected in plasma more frequently in cases compared to controls (p<0.001) for 5 out of 8 genes. The sensitivity and specificity for lung cancer diagnosis using the best individual gene was 64-85% and 55-79% respectively. A three-gene combination of the best individual genes has sensitivity and specificity of 92% and 78%. Area under the Receiver Operating Curve (AUC) for this panel was 0.90, 95% CI (0.86-0.96). Cross validation combining gene methylation with clinical information correctly predicted lung cancer in 86% of subjects using plasma detection. Furthermore, we analyzed the sensitivity and specificity of the same three-gene combination in cases subgroups regarding the tumor size and the results are as follow: in subgroup with tumor size of 2-3cm, the sensitivity and specificity were 94% and 87%, and the AUC was 0.96, 95% CI (0.91-0.99); in subgroup with tumor size of 1-2 cm, the sensitivity and specificity were 92% and 80%, and the AUC was 0.90, 95% CI (0.84-0.96); in subgroup with tumor size less than 1cm, the sensitivity and specificity decreased to 66% and 87%, and the AUC was 0.77, 95% CI (0.64-0.88). Conclusions: This study validates our previous study but in Chinese patients that it is possible to obtain high diagnostic accuracy for early stage NSCLC using a panel of methylated promoter genes in plasma samples with ultrasensitive MOB-qMSP, especially in patients with tumor of larger size. These epigenetic biomarkers could potentially be used to identify patients with high risk of lung cancer development.

Identification of a Panel of Candidate Epigenetic Biomarkers for Non-Small Cell Lung Cancer

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).

Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: A Validation Study in Chinese Patients.

Quantitative Assessment of Gene Promoter Methylation in Non-Small Cell Lung Cancer Using Methylation-Sensitive High-Resolution Melting.

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA

Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Methylation Status of Negative Regulators for Hedgehog Pathway in Early-Stage Non-Small-Cell Lung Cancer

A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma

Diagnostic Role of Wnt Pathway Gene Promoter Methylation in Non Small Cell Lung Cancer.

Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: a Study in Chinese Patients with Very Small Nodules.

Identification of Hyper-Methylated Sequences in Lung Cancer by Methylated CpG Island Amplification Coupled with Representational Difference Analysis

A Novel CpG Island Methylation Panel Predicts Survival in Lung Adenocarcinomas

Blood-based DNA Methylation Panel for the Early Diagnosis of Lung Cancer

Identification of a Novel CpG Methylation Signature to Predict Prognosis in Lung Squamous Cell Carcinoma

A Panel of Promoter Methylation Markers for Invasive and Noninvasive Early Detection of NSCLC Using a Quantum Dots-Based FRET Approach.

Identification and Validation of Colorectal Neoplasia-Specific Methylation Biomarkers Based on CTCF-binding Sites

Concomitant Hypermethylation of Multiple Genes in Non-Small Cell Lung Cancer (NSCLC)